Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Hospira can launch generic of Cubist's Cubicin, says court

Executive Summary

The US District Court ruled one of five key patents surrounding Cubist Pharmaceuticals Inc.'s nearly-$1bn antibiotic Cubicin (daptomycin) be upheld, paving the way for Hospira Inc. to launch its own generic version as early as June 2016. (The other four patents that were invalidated had expiration dates of 2018 and 2020, meaning that Hospira would have been forced to wait that much longer to get to the market.)
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register